Hideaki Jinnouchi Selected Research

Body Weight (Weight, Body)

12/2021	Changes in urinary glucose concentration and body weight in patients treated with the selective SGLT2 inhibitor luseogliflozin.
2/2020	Type 2 Diabetes Remission and Substantial Body Weight Reduction Achieved with Metformin and a Sodium-Glucose Cotransporter 2 Inhibitor.
4/2019	Renoprotective Effects of Additional SGLT2 inhibitor Therapy in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease Stages 3b-4: A Real World Report From A Japanese Specialized Diabetes Care Center.
6/2018	Dapagliflozin Reduces Fat Mass without Affecting Muscle Mass in Type 2 Diabetes.
6/2018	Impact of Dapagliflozin Therapy on Renal Protection and Kidney Morphology in Patients With Uncontrolled Type 2 Diabetes Mellitus.
1/2018	Clinical Factors Associated with Initial Decrease in Body-Fat Percentage Induced by Add-on Sodium-Glucose Co-transporter 2 Inhibitors in Patient with Type 2 Diabetes Mellitus.
1/2017	Improvement of quality of life through glycemic control by liraglutide, a GLP-1 analog, in insulin-naive patients with type 2 diabetes mellitus: the PAGE1 study.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Hideaki Jinnouchi Research Topics

Disease

38	Type 2 Diabetes Mellitus (MODY) 12/2021 - 05/2005
18	Atherosclerosis 11/2022 - 05/2005
12	Cardiovascular Diseases (Cardiovascular Disease) 02/2022 - 08/2009
10	Coronary Artery Disease (Coronary Atherosclerosis) 01/2021 - 05/2005
8	Insulin Resistance 12/2021 - 04/2014
7	Body Weight (Weight, Body) 12/2021 - 01/2017
7	Diabetes Mellitus 04/2021 - 04/2006
5	Hypertension (High Blood Pressure) 01/2019 - 10/2012
3	Hyperuricemia 06/2022 - 01/2017
3	Heart Failure 01/2021 - 07/2014
3	Chronic Renal Insufficiency 11/2020 - 01/2013
3	Diabetic Retinopathy (Retinopathy, Diabetic) 02/2017 - 09/2013
2	Kidney Diseases (Kidney Disease) 11/2022 - 01/2021
2	Inflammation (Inflammations) 06/2022 - 12/2010
2	Diabetic Nephropathies (Diabetic Nephropathy) 01/2022 - 01/2013
2	Spasm (Spasms) 01/2021 - 01/2021
2	Neoplasms (Cancer) 01/2021 - 01/2018
2	Dyslipidemias (Dyslipidemia) 05/2020 - 02/2017
2	Proteinuria 01/2020 - 01/2016
2	Obesity 01/2020 - 01/2018
2	Hemolysis 11/2019 - 02/2019
2	Hemorrhagic Stroke 02/2017 - 11/2008
2	Hemorrhage 02/2017 - 11/2008
2	Carotid Artery Diseases 01/2017 - 01/2016
1	Gout 02/2022
1	Hyperglycemia 04/2021
1	Diabetes Complications 02/2021
1	Coronary Stenosis (Coronary Artery Stenosis) 01/2021
1	Left Ventricular Dysfunction 01/2021
1	Fatty Liver 02/2020
1	Overweight 02/2020
1	Dementia (Dementias) 01/2020
1	Pulmonary Hypertension 01/2020
1	Atrial Fibrillation 01/2020
1	Anemia 01/2019
1	Tobacco Use Disorder (Nicotine Dependence) 06/2018
1	Albuminuria 01/2018
1	Hypoglycemia (Reactive Hypoglycemia) 01/2016
1	Type 1 Diabetes Mellitus (Autoimmune Diabetes) 06/2015
1	Liver Cirrhosis (Hepatic Cirrhosis) 01/2014
1	Hyperlipidemias (Hyperlipidemia) 01/2014

Drug/Important Bio-Agent (IBA)

18	Glucose (Dextrose)FDA LinkGeneric 12/2021 - 01/2012
14	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 11/2022 - 11/2008
10	Insulin (Novolin)FDA Link 04/2021 - 06/2011
8	Hemoglobins (Hemoglobin)IBA 02/2020 - 01/2016
6	SodiumIBA 11/2020 - 01/2016
5	Sodium-Glucose Transporter 2 InhibitorsIBA 12/2021 - 03/2016
5	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2021 - 01/2012
5	dapagliflozinIBA 02/2020 - 06/2018
4	Febuxostat FDA Link 06/2022 - 01/2017
4	AlbuminsIBA 01/2021 - 01/2016
4	Indicators and Reagents (Reagents)IBA 12/2019 - 10/2016
4	Insulin Glargine (Lantus)FDA Link 03/2017 - 12/2013
4	Glucagon-Like Peptide 1 (GLP 1)IBA 01/2017 - 01/2012
4	Dipeptidyl-Peptidase IV InhibitorsIBA 01/2017 - 01/2013
3	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 01/2022 - 06/2015
3	Calcium Channel Blockers (Blockers, Calcium Channel)IBA 01/2021 - 10/2012
3	Biomarkers (Surrogate Marker)IBA 01/2021 - 08/2009
3	Acetylcholine (Acetylcholine Chloride)FDA Link 01/2021 - 05/2005
3	SymportersIBA 08/2018 - 01/2018
3	CreatinineIBA 06/2018 - 01/2016
3	N- acetyl- S- (alpha- methyl- 4- (2- methylpropyl)benzeneacetyl)cysteine 4-(nitrooxy)butyl esterIBA 01/2018 - 06/2011
3	alogliptinIBA 01/2017 - 01/2013
3	Angiotensin Receptor AntagonistsIBA 01/2016 - 10/2012
2	C-Reactive ProteinIBA 06/2022 - 09/2013
2	Blood Glucose (Blood Sugar)IBA 12/2021 - 02/2021
2	1,5- anhydro- 1- (5- (4- ethoxybenzyl)- 2- methoxy- 4- methylphenyl)- 1- thioglucitolIBA 12/2021 - 03/2016
2	Insulin Lispro (Humalog)FDA Link 12/2020 - 09/2020
2	Metformin (Glucophage)FDA LinkGeneric 02/2020 - 01/2018
2	Sodium-Glucose Transport ProteinsIBA 02/2020 - 04/2019
2	CreatineIBA 11/2019 - 02/2019
2	Uric Acid (Urate)IBA 01/2019 - 01/2017
2	insulin degludecIBA 03/2017 - 09/2016
2	Hypoglycemic Agents (Hypoglycemics)IBA 03/2017 - 01/2015
2	Liraglutide FDA Link 01/2017 - 01/2015
2	Atorvastatin (Lipitor)FDA Link 04/2015 - 01/2012
2	LipidsIBA 01/2014 - 09/2013
2	Rosuvastatin Calcium (Crestor)FDA Link 01/2012 - 07/2011
1	NLR ProteinsIBA 06/2022
1	Proteins (Proteins, Gene)FDA Link 06/2022
1	InflammasomesIBA 06/2022
1	Antihypertensive Agents (Antihypertensives)IBA 01/2020
1	Prostaglandins AIBA 01/2020
1	AngiotensinsIBA 01/2018
1	Xanthine OxidaseIBA 01/2017
1	Telmisartan (Micardis)FDA Link 01/2016
1	LDL CholesterolIBA 01/2016
1	Ezetimibe (Zetia)FDA Link 04/2015
1	AdiponectinIBA 08/2014
1	PTX3 proteinIBA 07/2014
1	BilirubinIBA 01/2014
1	Branched-Chain Amino AcidsIBA 01/2014
1	Tryptophan (L-Tryptophan)FDA Link 01/2014

Therapy/Procedure

14	Therapeutics 02/2020 - 02/2011
9	Glycemic Control 11/2019 - 06/2011
3	Exercise Therapy (Therapy, Exercise) 08/2014 - 01/2012
2	Chemoprevention 01/2021 - 01/2018
1	Renal Dialysis (Hemodialysis) 11/2022
1	Secondary Prevention 02/2022
1	Critical Care (Surgical Intensive Care) 01/2021